'Older therapies are fast being replaced'. (Diabetes Care).
NEW YORK -- Current challenges and issues, an in-depth examination of market dynamics, and competitive analysis and technology trends within different segments of the diabetes therapy market are explored in a report released last year by Frost & Sullivan.
"Companies not having a market expansion plan in place and a weak product pipeline are expected to find it extremely challenging to maintain and grow their market share," predicts Ajit Bald, a research analyst in the health care group.
"The older therapies are fast being replaced by newer therapies -- pharmaceutical manufacturers realizing this attempt to shift their patients to their advanced therapies in order to protect their patient base. To continue with this transformation, the manufacturers invest in massive physician and patient awareness campaigns, which are expected to continue playing a key role in this market in the future."
Oral diabetes medications include sulfonylureas, biguanides, alpha-glucosidase inhibitors, glitazones and meglitinides. Biguanides and glitazones have continued to grow in popularity.
"It is estimated that the United States oral diabetes medications market generated revenues of $4.2 billion in 2001," states Baid.
Baid notes that the growth in the diabetes population has brought with it an expansion in the insulin-taking segment.
"Although many Type 2 diabetes patients that are eligible for insulin therapy evade its use due to fear of injections or concern of becoming insulin-dependent for the rest of their lives, insulin users continue to grow," he notes.
"Approximately 3.7 million diabetes patients in the U.S. used insulin therapy in 2001. The insulin therapy market was valued at $1.6 billion in the base year and is estimated to continue growing during the forecast period to 2008."
He points out that Aventis entered the U.S. insulin therapy market in 2001 with the launch of Lantus, a long-acting recombinant DNA (rDNA) analog insulin for use by both types of diabetes patients.
"The introduction of noninvasive insulin delivery technologies, the increasing insulin-taking population and the continued emphasis on insulin therapy are some of the factors that are likely to drive the growth of this market during the forecast period," notes Baid.
He adds that due to intense competition involved with each product, pharmaceutical manufacturers are joining hands to increase the probability of product success, resulting in more alliances and copromotion agreements than in the past.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||trends in the diabetes therapy market|
|Comment:||'Older therapies are fast being replaced'. (Diabetes Care).(trends in the diabetes therapy market)|
|Publication:||Chain Drug Review|
|Date:||Mar 17, 2003|
|Previous Article:||Pharmaceutical companies' R&D programs making steady gains. (Diabetes Care).|
|Next Article:||'It is imperative to have a well-stocked, well-assorted section'. (Diabetes Care).|